P347: Evaluation of step up therapy in patients with early ulcerative colitis: a prospective cohort studyECCO '17 Barcelona
2017
P348: Persistent hyperCKemia during infliximab therapy in patients with inflammatory bowel diseaseECCO '17 Barcelona
2017
P349: The therapies influencing postoperative surgical recurrence in Crohn's diseaseECCO '17 Barcelona
2017
P350: Induction of antiphospholipid antibodies in patients with inflammatory bowel disease treated with anti-TNFα agentsECCO '17 Barcelona
2017
P351: Do self-selected “Non-Transitioned” referrals from peadiatric services have lower treatment requirements?ECCO '17 Barcelona
2017
P352: Assessment of the use of therapeutic drug monitoring of Adalimumab during maintenance therapy in children with inflammatory bowel diseaseECCO '17 Barcelona
2017
P353: Long-term safety of adalimumab in patients with Crohn's disease: final data from PYRAMID registryECCO '17 Barcelona
2017
P354: The effect of value based health care delivery for inflammatory bowel diseases on outcomes of patientsECCO '17 Barcelona
2017
P355: A structured care pathway improves quality of care for acute severe ulcerative colitisECCO '17 Barcelona
2017
P356: Treatment with anakinra induces T cell production of IL22 and GI mucosal healing in an IL-10RA mutation patientECCO '17 Barcelona
2017
P357: A multi-institutional report of postoperative outcomes in Vedolizumab-Treated patients undergoing major abdominal operations for inflammatory bowel diseaseECCO '17 Barcelona
2017
P358: Efficacy of golimumab for the treatment of ulcerative colitis patients in clinical practice: a retrospective cohort studyECCO '17 Barcelona
2017
P359: Correlation between physician and patient disease assessments in ulcerative colitis: baseline data from the ICONIC study of 1816 patients in 33 countriesECCO '17 Barcelona
2017
P360: Trough levels and antibodies to ustekinumab are not correlated to response to ustekinumab treatment in Crohn's disease patientsECCO '17 Barcelona
2017
P361: Machine learning models at week 6 of vedolizumab therapy for ulcerative colitis can predict week 52 corticosteroid free endoscopic remissionECCO '17 Barcelona
2017
P362: Magnetic resonance healing predicts long-term outcomes in patients with Crohn's diseaseECCO '17 Barcelona
2017
P363: The impact of transition to adult gastroenterology services on health-related quality of life in young adult patients with IBD: the UK TRANSIT studyECCO '17 Barcelona
2017
P364: A Swedish observational study (SVEAH) on vedolizumab assessing effectiveness and healthcare resource utilization in patients with inflammatory bowel diseaseECCO '17 Barcelona
2017